We’re thrilled to announce that Helaina has raised a $45 Series B to accelerate the commercialization of bioactive proteins starting with effera™ human lactoferrin. This infusion of new capital marks our next phase of growth and is the result of years of our dedicated team’s work to drive innovation and scientific rigor within nutrition. At this pivotal moment in our journey, we’re proud to partner with Avidity Partners, an investment firm with an outstanding reputation for supporting best-in-class biotech companies rooted in clinically-backed science. To learn more about what we’re building and our commercial launch, check out AgFunder’s piece. https://lnkd.in/erAtXXya
Keep growing 🎆 🎆 🎆
Congratulations Laura Katz & Helaina team!
Congratulations on this remarkable milestone!